CPT code 0489U: Prenatal cfDNA test, single-gene fetal risk score2026 Medicare lab fee · Clinical Laboratory Fee Schedule
A prenatal cell-free DNA assay evaluates inherited variants and maternal mutation dosage to report a fetal risk score for selected single-gene conditions.
Medicare pays $1,153.62 for 0489U under the 2026 Clinical Laboratory Fee Schedule: one national amount, the same in every state and setting.
Medicare lab fee · CLFS 2026 Q4
National CLFS amount
$1,153.62
In effect since Jan 1, 2026. The same amount in every state, payment locality and setting.
- Geographic adjustment
- None
- Office vs facility
- Same
- Since 2026
- Unchanged
- CMS updates
- Quarterly
Medicare pays the lesser of the lab’s charge and this amount. Patients usually owe no Part B deductible or coinsurance for covered clinical lab tests.
On this page 7 sections
What 0489U covers
This obstetric noninvasive prenatal assay analyzes cell-free DNA to assess fetal inheritance of selected pathogenic variants. It can examine one or more targets, including genes associated with cystic fibrosis, spinal muscular atrophy, and hemoglobin disorders. The assay identifies paternally inherited variants and uses relative mutation-dosage analysis to assess whether a maternal mutation was inherited, producing a fetal risk score. It is used during pregnancy to evaluate risk for a selected single-gene condition.
Report 0489U for this single-gene prenatal assay, which may analyze one or more targets. Medicare pays it through the CLFS at one national amount that applies across states and localities, without geographic or office-versus-facility adjustment. The 2026 national CLFS amount is $1,153.62. 0489U is paid only through the CLFS and has no separately payable physician interpretation component.
This summary was written with AI assistance from CMS Clinical Laboratory Fee Schedule data. Amounts on this page come directly from CMS files.
How Medicare pays 0489U
Clinical lab tests aren’t priced like physician services. They’re paid from their own fee schedule, with its own rules. See the whole lab fee schedule.
One national amount
CMS sets a single Clinical Laboratory Fee Schedule amount for 0489U. There’s no geographic (GPCI) adjustment, so it pays the same in every state and payment locality.
No office or facility rate
Lab tests aren’t built from relative value units, so there’s no office and facility split: the place of service doesn’t change the CLFS amount.
Updated every quarter
CMS republishes the CLFS each quarter. New tests, often proprietary laboratory analyses (PLA codes), join during the year; existing amounts are updated each January.
Not on the physician fee schedule
The physician fee schedule doesn’t list 0489U: Medicare pays the test only from the CLFS.
0489U on the lab fee schedule since 2024
0489U · CLFS 2026 Q4 (current)
$1,153.62
Unchanged since Jan 1, 2026
Every change on file
- Jan 1, 2026 · CLFS 2026 Q1MAC-priced → $1,153.62
9 quarterly CLFS releases on file, first CLFS 2024 Q4. A code missing from a quarter wasn’t on that release.
0489U compared with similar tests
- 0488UFetal antigen testCell-free DNA, selected antigens$759.05
- 0488U is an obstetric fetal-antigen cell-free DNA test. 0489U assesses selected single-gene variants and reports a fetal risk score.
- 81420Fetal aneuploidyMaternal blood, genomic panel$759.05
- 81420 is used for cell-free DNA analysis of fetal chromosomal aneuploidy risk; 0489U addresses selected single-gene conditions.
- 81220CFTR analysisCommon variants$556.60
- 81220 analyzes CFTR variants, commonly for carrier or variant assessment. 0489U evaluates fetal risk during pregnancy through a cell-free DNA assay.
0489U billing questions
What clinical question does 0489U address?
It reports a fetal risk score for selected single-gene conditions by evaluating inherited variants and relative mutation dosage in prenatal cell-free DNA.
What does the assay's target scope cover?
The assay may analyze one or more targets, including genes associated with cystic fibrosis, spinal muscular atrophy, and hemoglobin disorders.
How does 0489U differ from 0488U?
0489U assesses selected single-gene inheritance and reports a fetal risk score. 0488U is an obstetric fetal-antigen cell-free DNA test.
Is a separate physician interpretation billed with 0489U?
No. 0489U is paid through the CLFS and has no separately payable physician interpretation component.
Does Medicare use a local rate for this test?
No. The CLFS amount is national and applies across states and localities, with no geographic or office-versus-facility adjustment.
Where this amount comes from
FeeBase reads lab amounts directly from the CMS Clinical Laboratory Fee Schedule file for the quarter: one row per code, with its payment indicator and national amount. Contractor-priced tests are labeled, never given a made-up amount. Amounts are Medicare payment limits, not a patient’s bill or a commercial rate.
CMS CLFS 2026 Q4 · effective Oct 1, 2026 through the day before Jan 1, 2027
Show the CMS file line behind this amount
Fee sheets · Coming soon
Put 0489U and the rest of your codes on one sheet
Your codes at your locality, with payer contracts beside Medicare.
Join the waitlist